4BIO Capital
Overview
4BIO Capital is a specialist fund focused on investing in and building early stage advanced therapy companies
Investment Focus
- Focus on advanced and emerging therapies
- Address high unmet medical needs
- Early-stage companies
- Viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome
Portfolio Companies
Reach 4BIO Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about 4BIO Capital
What sectors does 4BIO Capital invest in?
4BIO Capital invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Regenerative Medicine, and is based in London, England, United Kingdom. 4BIO Capital is listed as a vc in the ConnectSafely investor database.
What stage does 4BIO Capital invest at?
4BIO Capital backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 5M - 50M.
Which regions does 4BIO Capital invest in?
4BIO Capital invests across United States, United Kingdom, Germany, Japan, China and Switzerland.
Who are the partners at 4BIO Capital?
Team members listed for 4BIO Capital include Vasily Fedorin (Chief Operating Officer) and Dmitry Kuzmin (Managing Partner).
What companies has 4BIO Capital invested in?
4BIO Capital's portfolio includes Araris Biotech, March Biosciences and Trogenix.
How do I contact 4BIO Capital?
4BIO Capital's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
